EichorEICHOR
Condition: B Lymphoblastic Leukemia Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: B Lymphoblastic Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
Phase 1 · 1 location(s) · Liping Dou · NCT07677878Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT04560322NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL
Phase 1 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT05262673A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line
Phase 3 · 201 location(s) · Merck Sharp & Dohme LLC · NCT06136559Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
Phase 1 · 1 location(s) · CytoCares Inc · NCT06037018A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Maligna
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04532203Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma Wi
Phase 3 · 30 location(s) · AstraZeneca · NCT07509151CAR-T Immunotherapy Targeting CD19- ALL
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04016129CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 · 1 location(s) · Mayo Clinic · NCT04892277Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Rec
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06967610CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase 1 · 4 location(s) · Catapult Therapeutics · NCT04704323ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Phase 1 · 4 location(s) · Marlise Luskin, MD · NCT03595917Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functi
NA · 1 location(s) · University of Washington · NCT06710418Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06364423Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated C
Phase 3 · 182 location(s) · Alliance for Clinical Trials in Oncology · NCT07321652Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Phase 1 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT07532525Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
Phase 1 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06507514Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
Phase 2 · 20 location(s) · University Hospital, Clermont-Ferrand · NCT04935684CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
Phase 1 · 2 location(s) · St. Jude Children's Research Hospital · NCT04318678Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-deri
Phase 1 · 1 location(s) · Beijing GoBroad Hospital · NCT06326008Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematologi
Phase N/A · 5 location(s) · Medical University Innsbruck · NCT06821880Institut Paoli Calmettes Chronic Lymphatic Leukemia Database
Phase N/A · 1 location(s) · Institut Paoli-Calmettes · NCT02869529Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT07429461A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymph
Phase 3 · 143 location(s) · Loxo Oncology, Inc. · NCT05254743Evaluation of Skin Tests in Biotherapy Allergies
NA · 1 location(s) · University Hospital, Angers · NCT06971848Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
Phase 2 · 3 location(s) · Peter MacCallum Cancer Centre, Australia · NCT06812715Study on the Diagnosis and Management of CLL in Italy by GIMEMA
Phase N/A · 24 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT04867915Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT06980116Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810Phase Ib Clinical Study of Keynatinib
Phase 1 · 4 location(s) · Medolution Ltd. · NCT04807881
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.